|
- TEVIMBRA Received FDA Approval as First-Line Therapy for Gastric and . . .
The prognosis for patients with gastric or GEJ cancer depends on the stage at diagnosis, treatment response, and overall health Immunotherapies, such as TEVIMBRA (tislelizumab), offer a promising approach for first-line treatment in patients with PD-L1 positive advanced or metastatic gastric and GEJ cancers These newer treatments are vital
- Tevimbra Plus Chemo May Be Safe, Effective in Advanced Gastric GEJ Cancer
Tevimbra plus POFI demonstrated high efficacy with a 93 5% objective response rate and 100% disease control rate in advanced gastric cancer Median progression-free survival was 10 51 months, and overall survival was 14 75 months, indicating promising outcomes The treatment regimen was well
- FDA Approves Tislelizumab Plus Chemo for PD-L1+ Unresectable or . . .
Key Takeaways Tislelizumab-jsgr (Tevimbra) approved for first-line treatment of HER2-negative gastric or GEJ adenocarcinoma with PD-L1 expression
- FDA Approves Tislelizumab-jsgr (Tevimbra) Combo for Gastric or . . .
The U S Food and Drug Administration (FDA) approved tislelizumab-jsgr (Tevimbra) in combination with chemotherapy as a first-line treatment for adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinomas with programmed cell death ligand 1 (PD-L1) expression, according to a news release from BeiGene, the drug’s manufacturer
- TEVIMBRA® (tislelizumab-jsgr) for Gastric or Gastroesophageal Junction . . .
Treatment of gastric cancer often uses endoscopic resection, which may be curative in the early stages of the disease Given the high rate of relapse, neoadjuvant and adjuvant chemotherapy has become standard practice due to the robust data indicating increased rates of survival post-resection 1 Several targeted therapies and immunotherapies that increase patients’ overall survival in the
- FDA Approves Tevimbra Combination for Gastric or Gastroesophageal . . .
Tevimbra is a type of precision cancer medicine This humanized IgG4 anti-PD-1 monoclonal antibody was designed specifically to minimize binding to FcγR on macrophages RATIONALE-305 Investigators Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction
- FDA Approves Tislelizumab Chemo in Gastric GEJ Adenocarcinoma
The FDA previously accepted a biologics license application BLA for tislelizumab plus chemotherapy to treat patients with locally advanced or metastatic gastric or GEJ adenocarcinoma in February 2024 4 References TEVIMBRA approved in U S for first-line treatment of gastric and gastroesophageal junction cancers in combination with chemotherapy
- Tevimbra Approved in U. S. for First-line Treatment of Gastric and . . .
The additional indication for first-line G GEJ cancers is based on results from BeiGene’s RATIONALE-305 (NCT03777657), a randomized, double-blind, placebo-controlled, global Phase 3 trial to evaluate the efficacy and safety of Tevimbra in combination with chemotherapy as a first-line treatment for adult patients with advanced unresectable or
|
|
|